Teva v. Novartis: Post-MedImmune Declaratory Judgment

Law360, New York (April 25, 2007, 12:00 AM EDT) -- On March 30, 2007 the Federal Circuit decided a case that may have significant impact on litigation in the pharmaceutical industry. In Teva Phamaceuticals USA Inc., v. Novartis Pharmaceuticals Corp., 2007 U.S. App. Lexis 7383 (Fed. Cir. 2007), the Federal Circuit reversed the district court’s dismissal of Teva’s suit seeking a declaration that its generic famciclovir product did not infringe several of Novartis’ patents relating to Famvir®. This holding represents yet another significant departure from prior Federal Circuit case law in the area of declaratory judgment...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.